(Q33883229)

29 July 2017

title

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy (English)

1 reference

metastatic renal cell carcinoma

29 July 2017

1 reference

1 reference

S L Richey

1

1 reference

29 July 2017

S H Culp

2

1 reference

29 July 2017

E Jonasch

3

1 reference

29 July 2017

P G Corn

4

1 reference

29 July 2017

L C Pagliaro

5

1 reference

29 July 2017

P Tamboli

6

1 reference

29 July 2017

K K Patel

7

1 reference

29 July 2017

S F Matin

8

1 reference

29 July 2017

C G Wood

9

1 reference

29 July 2017

N M Tannir

10

1 reference

29 July 2017

publication date

29 November 2010

1 reference

29 July 2017

1 reference

29 July 2017

volume

22

1 reference

29 July 2017

issue

5

1 reference

29 July 2017

page(s)

1048-1053

1 reference

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Palliative percutaneous kidney embolization with enbucrilate in patients with renal cell carcinoma: safety and symptom control

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Renal artery embolisation in the palliative treatment of renal carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Sorafenib in advanced clear-cell renal-cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

The role of transarterial embolization in the treatment of renal cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Prognostic evaluation of transcatheter arterial embolization for unresectable renal cell carcinoma with distant metastasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Transcatheter arterial embolization of unresectable renal cell carcinoma with a mixture of ethanol and iodized oil.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

5 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ563

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ563

Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ563

A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ563

Prognostic factors for survival in patients with brain metastases from renal cell carcinoma

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

29 October 2018

Identifiers

DOI

10.1093/ANNONC/MDQ563

1 reference

29 July 2017

1 reference

29 July 2017

1 reference